Lymphomas are cancers of the lymphatic system. The lymphatic system drains excess fluid from tissues. It also helps protect against infections.
Non-Hodgkin lymphoma is a name that applies to many types of lymphomas. These types are based on the cell that is involved and the patterns of growth.
In general, these types can be classified as:
These cancers are different from Hodgkin lymphoma.
Copyright © Nucleus Medical Media, Inc.
Cancer occurs when cells in the body divide out of control or order. If cells keep dividing, a mass of tissue forms. These are called growths or tumors. If the tumor is cancer, it is called malignant. It can invade nearby tissue and spread to other parts of the body.
The cause of non-Hodgkin lymphoma is unknown. DNA mutations that occur after birth may be related to this cancer. These mutations can occur as a result of exposure to radiation or cancer-causing chemicals. They may also occur with age or for no apparent reason.
Most people who develop non-Hodgkin lymphoma have no known risk factors. Men and people age 60 to 70 years old are at increased risk. The following factors may also increase your chance of developing this condition:
You will be asked about your symptoms and medical history. A physical exam will be done. It will include an exam of your lymph nodes.
Your bodily fluids and tissues may be tested. This can be done with:
Imaging tests are used to view internal structures. Some may use contrast material to make structures easier to see. Imaging tests may include:
Treatments depend on the stage and type of cancer. The type is determined in part by a microscopic exam and other studies. Talk with your doctor about the best plan for you. Treatment options include:
For some indolent lymphomas, no treatment may be needed for some time. Treatment is needed if the tumor begins to cause symptoms. Treatment may also be needed if the tumor becomes too large to tolerate, or shows signs of becoming aggressive.
Chemotherapy involves the use of drugs to kill cancer cells. It may be given by pill, injection, or via a catheter (tube). The drugs enter the bloodstream and travel through the body. They will kill mostly cancer cells. Some healthy cells may also be killed.
Radiation is directed at the tumor from a source outside the body to kill the cancer cells.
You may be able to use your own bone marrow. Bone marrow is removed, treated, and frozen. Large doses of chemotherapy and/or radiation therapy are then applied to kill the cancer cells. After treatment, the bone marrow is replaced via a vein.
Marrow may also be donated by a healthy person.
Stem cells are immature cells that produce blood cells. They are removed from circulating blood before chemotherapy or radiation treatment. These cells are then replaced after treatment. The cells can then develop new, healthy cells.
These medications or substances are made by the body. They increase or restore the body’s natural defenses against cancer.
Interferons are one type of biological therapy. They interfere with the division of cancer cells and can slow tumor growth. Interferons are produced by the body. They can also be made in a lab to treat cancer and other diseases.
Sometimes, a drug or antibody that is directed at the lymphoma is linked to a radioactive substance. It will deliver a focused dose of radiation to the tumor.
There are no guidelines for preventing non-Hodgkin lymphoma. To reduce your risk, avoid exposure to chemicals such as herbicides, pesticides, benzene, and chlorinated organic solvents. If you have celiac disease, maintain your gluten-free diet. This diet will minimize stimulation of your immune system from exposure to gluten.
American Cancer Society
Leukemia & Lymphoma Society
Canadian Cancer Society
Adult non-Hodgkin lymphoma treatment (PDQ)-patient version. National Cancer Institute website. Available at: https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed January 28, 2021.
Non-Hodgkin lymphoma (adults). American Cancer Society website. Available at: https://www.cancer.org/cancer/non-hodgkin-lymphoma.html. Accessed January 28, 2021.
7/7/2014 DynaMed Plus Systematic Literature Surveillancehttp://www.dynamed.com/topics/dmp~AN~T116014/Non-Hodgkin-lymphoma-NHL: Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-1156.
Last reviewed December 2020 by EBSCO Medical Review Board Mohei Abouzied, MD, FACP Last Updated: 1/28/2021